Codexis, Inc.
NASDAQ:CDXSBiotechnology
+$0.02 today
- Market cap
- $126.04M
- Beta
- 2.48
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.35
Volume 1.47M
Average 1.15M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Codexis, Inc.
NASDAQ:CDXS
Intrinsic Alpha fair value
Locked
Current Price
$1.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -20.2% | +19.1% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -20.2% over three years. Forward estimates point to Revenue at +19.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
OmniAb, Inc. NASDAQ:OABI | $716.17M | $4.91 | Not rated | -5.2 | +215.53% |
C4 Therapeutics, Inc. NASDAQ:CCCC | $362.43M | $2.76 | Not rated | -4.9 | -0.20% |
Invivyd, Inc. NASDAQ:IVVD | $171.58M | $0.58 | Not rated | -3.9 | -81.40% |
Protara Therapeutics, Inc. NASDAQ:TARA | $155.77M | $2.53 | Not rated | -2.7 | -65.33% |
Innate Pharma S.A. NASDAQ:IPHA | $154.15M | $1.38 | Not rated | -3.0 | -42.78% |
Armata Pharmaceuticals, Inc. AMEX:ARMP | $143.89M | $3.87 | Not rated | -0.9 | -53.92% |
Insight Molecular Diagnostics Inc. NASDAQ:IMDX | $70.03M | $2.14 | Not rated | -3.9 | -74.88% |
Rani Therapeutics Holdings, Inc. NASDAQ:RANI | $34.38M | $0.53 | Not rated | -4.6 | -57.04% |
Sangamo Therapeutics, Inc. NASDAQ:SGMO | $30.66M | $0.07 | Not rated | -0.5 | -58.46% |
Continue the stock analysis
Jump to another research area for this company.